XORTX Therapeutics Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Share capital and reserves - Issuances (Details)

Share capital and reserves - Issuances (Details)										12 Months Ended
Share capital and reserves - Issuances (Details)	Dec. 29, 2022 CAD ($) shares	Dec. 29, 2022 USD ($) $ / shares shares	Oct. 07, 2022 CAD ($) shares	Oct. 07, 2022 USD ($) $ / shares shares	Nov. 08, 2021 CAD ($) shares	Nov. 08, 2021 USD ($) $ / shares shares	Oct. 15, 2021 $ / shares	Feb. 09, 2021 CAD ($) shares	Feb. 09, 2021 CAD ($) $ / shares	Dec. 31, 2022 CAD ($)	Dec. 31, 2021 CAD ($) shares	Oct. 07, 2022 $ / shares	Feb. 09, 2021 $ / shares
Disclosure of classes of share capital [line items]
Price per unit \| $ / shares						$ 4.13
Aggregate gross proceeds					$ 1,825,159	$ 1,466,150
Number of warrants issued					3,341,900	3,341,900
Issuance costs recorded as a reduction of equity \| $											$ 75,000
Value of shares issued from exercise of warrants \| $										$ 87	2,855,983
Amount transferred from reserves to share capital \| $											$ 65,172
Warrant
Disclosure of classes of share capital [line items]
Exercise price of warrants \| $ / shares							$ 4.77
Warrants expiration term							5 years
Number of shares issued upon exercise of warrants											651,583
Value of shares issued from exercise of warrants \| $											$ 2,430,083
Amount transferred from reserves to share capital \| $											32,387
Private placement
Disclosure of classes of share capital [line items]
Number of units issued								2,085,687
Price per unit \| $ / shares									$ 2.935
Number of shares per unit								1
Number of warrant per unit								1
Number of shares per warrant								1
Aggregate gross proceeds			$ 6,855,506	$ 4,999,640				$ 6,121,572
Exercise price of warrants \| $ / shares													$ 4.70
Warrants expiration term								5 years
Proceeds allocated to derivative warrant liability \| $			5,093,593								5,358,000
Proceeds allocated to common shares \| $			493,474								$ 763,572
Proceeds allocated to pre-funded warrants \| $			1,268,439
Issuance costs \| $			1,438,127
Issuance costs recorded as a reduction of equity \| $			435,065					$ 41,068
Transaction costs on derivative warrant liability and pre-funded warrants \| $			$ 1,257,746					$ 287,946
Private placement \| Common Share Units
Disclosure of classes of share capital [line items]
Number of units issued			1,400,000	1,400,000
Price per unit \| $ / shares				$ 1.00
Number of shares per unit			1	1
Number of warrant per unit			1	1
Number of shares per warrant			1	1
Private placement \| Pre-Funded Units
Disclosure of classes of share capital [line items]
Number of units issued			3,600,000	3,600,000
Price per unit \| $ / shares				$ 0.9999
Number of shares per unit			1	1
Number of warrant per unit			1	1
Number of shares per warrant			1	1
Private placement \| Warrant \| Pre-Funded Units
Disclosure of classes of share capital [line items]
Exercise price of warrants \| $ / shares												$ 1.22
Warrants expiration term			5 years	5 years
Private placement \| Pre-Funded Warrant
Disclosure of classes of share capital [line items]
Price per unit \| $ / shares		$ 0.0001
Number of shares issued upon exercise of warrants	641,000	641,000
Value of shares issued from exercise of warrants	$ 87	$ 64
Amount transferred from reserves to share capital \| $	$ 225,842
Private placement \| Pre-Funded Warrant \| Common Share Units
Disclosure of classes of share capital [line items]
Exercise price of warrants \| $ / shares												$ 0.0001
Private placement \| Finders' warrants
Disclosure of classes of share capital [line items]
Exercise price of warrants \| $ / shares													$ 4.70
Number of warrants issued			250,000	250,000				58,288
Fair value of warrants \| $			$ 254,684					$ 150,000	$ 150,000